Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Deutsche Boerse AG
  5. Apontis Pharma AG
  6. News
  7. Summary
    APPH   DE000A3CMGM5

APONTIS PHARMA AG

(APPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE : APONTIS PHARMA AG: Initial studies confirm that the share has a price potential of between 77% and 135%

06/18/2021 | 01:32am EDT
DGAP-News: APONTIS PHARMA AG / Key word(s): Research Update 
APONTIS PHARMA AG: Initial studies confirm that the share has a price potential of between 77% and 135% 
2021-06-18 / 07:30 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
APONTIS PHARMA AG: Initial studies confirm that the share has a price potential of between 77% and 135% 
Monheim am Rhein, 18 June 2021. The analysts at Hauck & Aufhäuser and Warburg Research have initiated coverage of the 
APONTIS PHARMA AG share (Ticker APPH / ISIN DE000A3CMGM5). In their initial study, the experts attest APONTIS an 
early-mover advantage in the market for Single Pills, which the company can convert into market share by accelerating 
the development of its broad product pipeline thanks to the fresh funds from the IPO, among other things. 
Accordingly, Hauck & Aufhäuser analyst Aliaksandr Halitsa expects consolidated sales to grow by an average of 20% per 
year to EUR 96 million by the 2025 financial year, driven by market share gains and new products from the Single Pill 
pipeline. Due to the high scalability, the experts expect EBIT to increase to EUR 27 million in the same period, which 
corresponds to an EBIT margin of 28%. 
Based on a DCF model, Hauck & Aufhäuser sees a price target of EUR 31.00. From the current price level of EUR 17.50, 
this corresponds to a price potential of 77%. 
Warburg Research is even more confident in its initial assessment. The favorable global market trends such as the 
expanding Single Pill submarket, an aging society, the increasing relevance of combination therapies and stagnating R&D 
innovations in the industry provide APONTIS PHARMA with high growth potential, according to the experts. 
The company currently has eight Single Pill products in its portfolio and has already achieved impressive growth rates 
of 250% to 800% with these products since market launch, according to Warburg analyst Dr. Christian Ehmann. Continuing 
on this path, APONTIS has four products in the short-term and 12 further projects for medium-term market entry in the 
pipeline, the expert added. 
The Warburg analyst estimates sales of EUR 108.3 million by 2025 and considers an EBITDA of EUR 31.7 million to be 
achievable. Based on the current forecasts, Warburg Research derives a price target of EUR 41.00, which corresponds to 
a price potential of 135% based on the DCF model. The contact details of the analysts are available at the following 
link: https://ir.apontis-pharma.de/websites/apontispharma/English/2000/share-price.html 
About APONTIS PHARMA: 
APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pills in Germany. Single Pills combine two 
to three generic active ingredients in a single dosage form. APONTIS PHARMA develops, promotes and sells a broad 
portfolio of Single Pills and other pharmaceutical products, with a special focus on cardiovascular diseases. Since 
2013, APONTIS successfully launched several Single Pill products alone for cardiovascular indications such as 
hypertension, hyperlipidemia and secondary prevention. With its headquarters in Monheim am Rhein, APONTIS PHARMA is 
located in one of Europe's leading pharmaceutical and chemical region. From here, the company maintains a broad network 
with research-based pharmaceutical companies and a customer target group of approx. 23,000 physicians in Germany. For 
additional information about APONTIS PHARMA, please visit www.apontis-pharma.de. 
APONTIS PHARMA AG 
Investor Relations 
ir@apontis-pharma.de 
T: +49 2173 89 55 4900 
F: +49 2173 89 55 1521 
Alfred-Nobel-Str. 10 
40789 Monheim am Rhein 
Deutschland 
apontis-pharma.de 
APONTIS PHARMA Press-Contact 
CROSS ALLIANCE 
Sven Pauly 
Sara Pinto 
ir@apontis-pharma.de 
T: +49 89 125 09 0330 
www.crossalliance.de 
=---------------------------------------------------------------------------------------------------------------------- 
2021-06-18 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      APONTIS PHARMA AG 
              Alfred-Nobel-Str. 10 
              40789 Monheim 
              Germany 
E-mail:       info@apontis-pharma.de 
Internet:     https://apontis-pharma.de/ 
ISIN:         DE000A3CMGM5 
WKN:          A3CMGM 
Listed:       Regulated Unofficial Market in Frankfurt (Scale) 
EQS News ID:  1209368 
 
End of News   DGAP News Service 
=------------ 

1209368 2021-06-18

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1209368&application_name=news 
 

(END) Dow Jones Newswires

June 18, 2021 01:31 ET (05:31 GMT)

All news about APONTIS PHARMA AG
07/12PRESS RELEASE : APONTIS PHARMA marks further success in the roll-out of Single P..
DJ
07/12APONTIS PHARMA : marks further success in the roll-out of Single Pill therapy
EQ
06/18PRESS RELEASE : APONTIS PHARMA AG: Initial studies confirm that the share has a ..
DJ
06/18APONTIS PHARMA AG : Initial studies confirm that the share has a price potential..
EQ
06/10PRESS RELEASE : APONTIS PHARMA AG: Post-Stabilisation disclosure - Partial exerc..
DJ
06/10APONTIS PHARMA AG : Post-Stabilisation disclosure - Partial exercise of the Gree..
EQ
06/10PRESS RELEASE : APONTIS PHARMA AG: Notification on -2-
DJ
06/10PRESS RELEASE : APONTIS PHARMA AG: Notification on the implementation of stabili..
DJ
06/10APONTIS PHARMA AG : Notification on the implementation of stabilization measures
EQ
05/28PRESS RELEASE : APONTIS PHARMA AG: Notification on the implementation of stabili..
DJ
More news
Financials
Sales 2021 48,7 M 57,3 M 57,3 M
Net income 2021 2,90 M 3,41 M 3,41 M
Net cash 2021 28,8 M 33,8 M 33,8 M
P/E ratio 2021 53,9x
Yield 2021 -
Capitalization 158 M 186 M 186 M
EV / Sales 2021 2,66x
EV / Sales 2022 2,24x
Nbr of Employees 195
Free-Float -
Chart APONTIS PHARMA AG
Duration : Period :
Apontis Pharma AG Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 18,60 €
Average target price 36,00 €
Spread / Average Target 93,5%
EPS Revisions
Sector and Competitors
1st jan.Capi. (M$)
APONTIS PHARMA AG0.00%179
JOHNSON & JOHNSON8.01%432 430
ROCHE HOLDING AG11.02%325 975
PFIZER, INC.12.66%218 198
ELI LILLY AND COMPANY41.25%209 276
NOVARTIS AG0.20%207 246